Literature DB >> 25767223

Complete Genome Sequence of a Metronidazole-Resistant Helicobacter pylori Strain.

Tran Thanh Binh1, Rumiko Suzuki1, Dong Hyeon Kwon2, Yoshio Yamaoka3.   

Abstract

We report here the complete genome sequence of a metronidazole-resistant Helicobacter pylori strain (MET(r)). The MET(r) strain was obtained under exposure of H. pylori 26695 on agar plates with low metronidazole concentrations. The genome data provide insight into the genomic changes of H. pylori under selection by metronidazole in vitro.
Copyright © 2015 Binh et al.

Entities:  

Year:  2015        PMID: 25767223      PMCID: PMC4357745          DOI: 10.1128/genomeA.00051-15

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Helicobacter pylori is a spiral Gram-negative bacterium that infects more than half of the world’s population and is a major cause of chronic gastritis, peptic ulcer diseases, gastric cancer, and mucosa-associated lymphoid tissue lymphoma (MALT) (1, 2). The eradication of H. pylori not only improves peptic ulcer healing but also prevents its recurrence and reduces the risk of developing gastric cancer (3–6). Metronidazole has been widely used in combination with therapies, such as metronidazole-based triple therapy, concomitant therapy, and bismuth-containing quadruple therapy, to eradicate this bacterium (6–8). Although treatment success depends on several factors, such as smoking status and patient compliance, antibiotic resistance is the major cause (9–11). However, along with clarithromycin resistance, resistance to metronidazole has arisen independently and is becoming increasingly common (12, 13). In the present report, we announce the genome sequence of a metronidazole (MET)-resistant (METr) H. pylori strain obtained in vitro. The genome of the strain provides insight into the genomic changes of H. pylori under MET selection. The METr strain was obtained under the exposure to a low concentration of MET in vitro (up to 16.0 µg/ml MET in an agar plate), and whole-genome sequencing was performed using 90-base paired-end reads on the Illumina HiSeq 2000 genome sequencer (Illumina, Inc., San Diego, CA). The whole-genome sequence of the strain was reconstructed by mapping the short-read sequences on the genome of H. pylori 26695 (GenBank accession no. NC_000915) using CLC Genomics Workbench version 4.0 (CLC bio, Aarhus, Denmark). The length of 26695-1MET genome is 1,667,302 bp, with a coverage depth of 680×. The G+C content of this strain is 38.87%. Three mutations in 3 genes were found in the H. pylori METr strain, including the mutations in the rdxA (hp0954) and frxA (hp0642) genes (14). The new mutation (G37T) was found in the gene rpsU (hp0562).

Nucleotide sequence accession number.

The genome sequence of the metronidazole-resistant H. pylori strain (26695-1MET) was deposited at GenBank under the accession no. CP010436.
  14 in total

Review 1.  Helicobacter pylori treatment in the era of increasing antibiotic resistance.

Authors:  David Y Graham; Lori Fischbach
Journal:  Gut       Date:  2010-06-04       Impact factor: 23.059

Review 2.  Worldwide H. pylori antibiotic resistance: a systematic review.

Authors:  Vincenzo De Francesco; Floriana Giorgio; Cesare Hassan; Gianpiero Manes; Lucy Vannella; Carmine Panella; Enzo Ierardi; Angelo Zullo
Journal:  J Gastrointestin Liver Dis       Date:  2010-12       Impact factor: 2.008

3.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

4.  Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type.

Authors:  R Takenaka; H Okada; J Kato; C Makidono; S Hori; Y Kawahara; M Miyoshi; E Yumoto; A Imagawa; T Toyokawa; K Sakaguchi; Y Shiratori
Journal:  Aliment Pharmacol Ther       Date:  2007-04-01       Impact factor: 8.171

5.  Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal.

Authors:  Vincenzo De Francesco; Angelo Zullo; Cesare Hassan; Floriana Giorgio; Rosa Rosania; Enzo Ierardi
Journal:  World J Gastrointest Pathophysiol       Date:  2011-06-15

6.  Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection.

Authors:  K Ming Fock; Peter Katelaris; Kentaro Sugano; Tiing Leong Ang; Richard Hunt; Nicholas J Talley; Shiu Kum Lam; Shu-Dong Xiao; Huck Joo Tan; Chun-Ying Wu; Hyun Chae Jung; Bui Huu Hoang; Udom Kachintorn; Khean-Lee Goh; Tsutomu Chiba; Abdul Aziz Rani
Journal:  J Gastroenterol Hepatol       Date:  2009-10       Impact factor: 4.029

Review 7.  Review article: the treatment of refractory Helicobacter pylori infection.

Authors:  F Mégraud; H Lamouliatte
Journal:  Aliment Pharmacol Ther       Date:  2003-06-01       Impact factor: 8.171

Review 8.  Smoking increases the treatment failure for Helicobacter pylori eradication.

Authors:  Takeshi Suzuki; Keitaro Matsuo; Hidemi Ito; Akira Sawaki; Kaoru Hirose; Kenji Wakai; Shigeki Sato; Tsuneya Nakamura; Kenji Yamao; Ryuzo Ueda; Kazuo Tajima
Journal:  Am J Med       Date:  2006-03       Impact factor: 4.965

9.  Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial.

Authors:  S W Hosking; T K Ling; S C Chung; M Y Yung; A F Cheng; J J Sung; A K Li
Journal:  Lancet       Date:  1994-02-26       Impact factor: 79.321

10.  Management of Helicobacter pylori.

Authors:  Seiji Shiota; Yoshio Yamaoka
Journal:  F1000 Med Rep       Date:  2010-03-15
View more
  2 in total

1.  The Bioinformatics Report of Mutation Outcome on NADPH Flavin Oxidoreductase Protein Sequence in Clinical Isolates of H. pylori.

Authors:  Nasrin Mirzaei; Farkhondeh Poursina; Sharareh Moghim; Abdol Majid Ghaempanah; Hajieh Ghasemian Safaei
Journal:  Curr Microbiol       Date:  2016-01-28       Impact factor: 2.188

2.  Cholestenone functions as an antibiotic against Helicobacter pylori by inhibiting biosynthesis of the cell wall component CGL.

Authors:  Junichi Kobayashi; Masatomo Kawakubo; Chifumi Fujii; Nobuhiko Arisaka; Masaki Miyashita; Yoshiko Sato; Hitomi Komura; Hisanori Matoba; Jun Nakayama
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-20       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.